A team of researchers from the Hebrew University of Jerusalem, the Weizmann Institute of Science, and the University of Tokyo has made a significant breakthrough in the fight against cancer by developing a highly selective inhibitor for an enzyme called Matrix Metallopeptidase 7 (MMP7).